Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons

Ignacio Mejía-Calvo, Leslie Muñoz-García, Alexis Jiménez-Uribe, Rosa Camacho-Sandoval, Edith González-González, Gabriela Mellado-Sánchez, Alejandra V. Tenorio-Calvo, Carlos A. López-Morales, Marco A. Velasco-Velázquez, Lenin Pavón, Sonia Mayra Pérez-Tapia, Emilio Medina-Rivero

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The biotherapeutic type I interferons (IFN-I) are indicated to treat several diseases. These products are regulated to guarantee safety and efficacy through critical quality attributes. For this purpose, the development of robust assays is required, followed by its validation to demonstrate their suitability for its intended purpose. Despite there are some commercial kits to evaluate IFN-I signaling, these are focused on measuring in vitro biological response instead of their validation, which is a pharmaceutical industry requirement. The aim of this work was to validate the HEK-Blue IFN-α/β system evaluating the biological activity of IFN-α/β under good laboratory practices, according to international standards. Our results demonstrated that HEK-Blue IFN-α/β system comply with accuracy (r2>0.95) precision (CV < 20%) and specificity for both IFN-α/β; confirming that this assay is robust for this biotherapeutics’ evaluation. Thereby, this bioassay could be implemented as a complementary method to the classical anti-proliferative and anti-viral assays under quality control environments.

    Original languageEnglish
    Article numbere00331
    JournalBiotechnology Reports
    Volume22
    DOIs
    StatePublished - Jun 2019

    Keywords

    • Bioassay
    • Biotherapeutic products
    • Interferons α/β
    • Receptor binding

    Fingerprint

    Dive into the research topics of 'Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons'. Together they form a unique fingerprint.

    Cite this